Novartis And Maruho To Co-Promote Psoriasis Drug Secukinumab
This article was originally published in PharmAsia News
Executive Summary
Novartis and Maruho have entered into an agreement to co-promote the human IL-17A monoclonal antibody secukinumab in Japan, the companies announced on July 16.